Dossier assessment

Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-142
Last updated

Report documents

  1. Extract of dossier assessment

    Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 366 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-142_en
  2. Dossier assessment

    Empagliflozin (type 2 diabetes mellitus in children and adolescents) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 577 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-142

Dossier assessment

Indication:

Children and adolescents aged 10 to 17 years with type 2 diabetes mellitus who have not achieved sufficient blood glucose control with their previous drug therapy consisting of at least one blood glucose-lowering drug as an adjunct to diet and exercise

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A23-142
Commission
Commission awarded on 20.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-142_en

Connected Projects

  1. Addendum

    Empagliflozin - Addendum to Commission A16-12

    Project no.
    A16-46
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    Project no.
    A14-26
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Empagliflozin - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-12
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V

    Project no.
    A23-78
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-39
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-93
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form